Atlas Trials

Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan

Clinical trial NCT02402699 · COMPLETED

Trial details

NCT number
NCT02402699
Sponsor
Bristol-Myers Squibb
Status
COMPLETED
Study type
OBSERVATIONAL
Advanced MelanomaHepatitis BHepatitis C
Start date
2015-12-15
Primary completion
2017-03-23
Enrollment
3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.